These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 25448574)

  • 1. Self-assembled drug delivery systems. Part 8: In vitro/in vivo studies of the nanoassemblies of cholesteryl-phosphonyl gemcitabine.
    Li M; Qi S; Jin Y; Dong J
    Int J Pharm; 2015 Jan; 478(1):124-130. PubMed ID: 25448574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-assembled drug delivery systems. Part 6: in vitro/in vivo studies of anticancer N-octadecanoyl gemcitabine nanoassemblies.
    Jin Y; Lian Y; Du L; Wang S; Su C; Gao C
    Int J Pharm; 2012 Jul; 430(1-2):276-81. PubMed ID: 22486963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N-dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma.
    Du L; Zhang B; Lei Y; Wang S; Jin Y
    Biomed Pharmacother; 2016 Apr; 79():208-14. PubMed ID: 27044830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomimetic nanoassemblies of 1-O-octodecyl-2-conjugated linoleoyl-sn-glycero-3-phosphatidyl gemcitabine with phospholipase A
    Zuo J; Tong L; Du L; Yang M; Jin Y
    Colloids Surf B Biointerfaces; 2017 Apr; 152():467-474. PubMed ID: 28187380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-assembled drug delivery systems. Part 7: hepatocyte-targeted nanoassemblies of an adefovir lipid derivative with cytochrome P450-triggered drug release.
    Du L; Wu L; Jin Y; Jia J; Li M; Wang Y
    Int J Pharm; 2014 Sep; 472(1-2):1-9. PubMed ID: 24929012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-assembled drug delivery systems. Part 4. In vitro/in vivo studies of the self-assemblies of cholesteryl-phosphonyl zidovudine.
    Jin Y; Xing L; Tian Y; Li M; Gao C; Du L; Dong J; Chen H
    Int J Pharm; 2009 Oct; 381(1):40-8. PubMed ID: 19646518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
    Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
    Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine.
    Dubey RD; Alam N; Saneja A; Khare V; Kumar A; Vaidh S; Mahajan G; Sharma PR; Singh SK; Mondhe DM; Gupta PN
    Int J Pharm; 2015 Aug; 492(1-2):80-91. PubMed ID: 26165611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
    Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
    Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
    Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
    Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular self-assembly of amphiphilic cyclic phosphoryl gemcitabine with different N-fatty acyl tails and enhanced anticancer effects of the self-assembled nanostructures.
    Jin Y; Wang S; Yao W; Du L
    Colloids Surf B Biointerfaces; 2015 Sep; 133():356-61. PubMed ID: 26143151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revealing the impact of modified modules flexibility on gemcitabine prodrug nanoassemblies for effective cancer therapy.
    Guo J; Zhang X; Dong F; Wang S; Wang D; Li Y; Zuo S; Wang Q; Li W; Sun J; He Z; Zhang T; Jiang Q; Sun B
    J Colloid Interface Sci; 2025 Jan; 677(Pt A):941-952. PubMed ID: 39128288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer.
    Liang TJ; Zhou ZM; Cao YQ; Ma MZ; Wang XJ; Jing K
    Int J Pharm; 2016 Nov; 513(1-2):564-571. PubMed ID: 27613255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
    Tang Z; Feng W; Yang Y; Wang Q
    Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies.
    Bekkara-Aounallah F; Ambike A; Gref R; Couvreur P; Rosilio V
    Int J Pharm; 2014 Aug; 471(1-2):75-82. PubMed ID: 24811925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
    Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
    J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
    Senanayake TH; Warren G; Wei X; Vinogradov SV
    J Control Release; 2013 Apr; 167(2):200-9. PubMed ID: 23385032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol derivative-based liposomes for gemcitabine delivery: preparation, in vitro, and in vivo characterization.
    Li T; Chen L; Deng Y; Liu X; Zhao X; Cui Y; Shi J; Feng R; Song Y
    Drug Dev Ind Pharm; 2017 Dec; 43(12):2016-2025. PubMed ID: 28760000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model.
    Guo P; Ma J; Li S; Guo Z; Adams AL; Gallo JM
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):169-76. PubMed ID: 11561783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.